C
카이노스메드
284620KOSDAQ자연과학 및 공학 연구개발업49.0 / 100
Reference Date: 2026-04-13
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure7.0 / 15
AI Analysis: PBR raises overvaluation concerns, ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Kainosmed is a biotech company focused on developing innovative therapies for incurable and rare diseases, generating revenue through licensing out drug candidates. The company is currently advancing Parkinson's disease treatments and HIV therapies into Phase 2 clinical trials, while also exploring oncology drug development.
Number of Employees
15people
Average Salary
73.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
7.81Industry Average 3.820.0Point
2.0x industry avg (risky)
ROE
-148.61Industry Average -32.113.5Point
4.6x industry avg (excellent)
Debt Ratio
—Industry Average 7.524.0Point
Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲109.7% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲37.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -109.3% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (22%)
Current 1,087Won52-week high 1,46052-week low 977
1-month return3.0Point
1m 0% (flat)
Volume trend6.0Point
Volume surge
Detailed Disclosure
9 totalPositive 0Neutral 8Negative 1
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
- Neutral정기주주총회결과2026-03-31
- Neutral감사보고서제출2026-03-23
- Neutral사업보고서 (2025.12)2026-03-23
- Negative기타시장안내 ('25사업연도 감사의견 거절 관련 상장폐지 절차 미진행)2026-03-23